Bioverativ Inc to Post FY2017 Earnings of $2.51 Per Share, William Blair Forecasts (BIVV)
Bioverativ Inc (NASDAQ:BIVV) – Stock analysts at William Blair raised their FY2017 earnings per share (EPS) estimates for Bioverativ in a research note issued on Monday. William Blair analyst R. Prasad now anticipates that the biotechnology company will earn $2.51 per share for the year, up from their previous forecast of $2.50. William Blair also issued estimates for Bioverativ’s Q4 2017 earnings at $0.54 EPS, FY2018 earnings at $2.68 EPS, FY2019 earnings at $2.70 EPS and FY2020 earnings at $2.62 EPS.
Bioverativ (NASDAQ:BIVV) last posted its earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.55 by $0.25. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%. The company had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. The business’s quarterly revenue was up 27.2% compared to the same quarter last year. COPYRIGHT VIOLATION WARNING: “Bioverativ Inc to Post FY2017 Earnings of $2.51 Per Share, William Blair Forecasts (BIVV)” was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/11/02/bioverativ-inc-to-post-fy2017-earnings-of-2-51-per-share-william-blair-forecasts-bivv.html.
A number of other research analysts also recently issued reports on the company. Zacks Investment Research downgraded Bioverativ from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. Piper Jaffray Companies reiterated an “overweight” rating and set a $71.00 price target on shares of Bioverativ in a research note on Monday, October 23rd. Morgan Stanley reiterated an “underweight” rating and set a $47.00 price target (up previously from $45.00) on shares of Bioverativ in a research note on Friday, October 6th. Argus upgraded Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Wednesday, September 20th. Finally, Royal Bank Of Canada started coverage on Bioverativ in a research note on Thursday, September 14th. They set a “sector perform” rating and a $59.00 price target for the company. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $61.73.
In related news, Director Louis J. Paglia acquired 2,000 shares of the company’s stock in a transaction that occurred on Monday, August 7th. The shares were acquired at an average price of $59.70 per share, with a total value of $119,400.00. Following the acquisition, the director now owns 5,056 shares of the company’s stock, valued at approximately $301,843.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian S. Posner acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The shares were bought at an average cost of $59.19 per share, for a total transaction of $59,190.00. Following the acquisition, the director now directly owns 6,693 shares in the company, valued at approximately $396,158.67. The disclosure for this purchase can be found here.
A number of institutional investors and hedge funds have recently modified their holdings of BIVV. Woodford Investment Management Ltd purchased a new stake in Bioverativ during the 3rd quarter worth about $85,455,000. Old Mutual Global Investors UK Ltd. purchased a new stake in shares of Bioverativ in the 3rd quarter valued at about $96,827,000. Frontier Capital Management Co. LLC purchased a new stake in shares of Bioverativ in the 3rd quarter valued at about $54,653,000. American Century Companies Inc. purchased a new stake in shares of Bioverativ in the 3rd quarter valued at about $48,168,000. Finally, First Trust Advisors LP purchased a new stake in shares of Bioverativ in the 3rd quarter valued at about $38,238,000. 92.93% of the stock is currently owned by institutional investors and hedge funds.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.